0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Neuregulin-4

Neuregulin-4

Brief Information

Name:Neuregulins
Target Synonym:Neuregulins
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

Neuregulin-4,NRG4

Background

Neuregulin 4 also known as NRG4 is a member of the neuregulin protein family which in humans is encoded by the NRG4 gene. Loss of expression of NRG4 is frequently seen in advanced bladder cancer while increased NRG4 expression correlates to better survival. The neuregulins, including NRG4, activate type-1 growth factor receptors (EGFR) to initiating cell-to-cell signaling through tyrosine phosphorylation. Furthermore, NRG4 is a low affinity ligand for the ERBB4 tyrosine kinase receptor. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. NRG4 does not bind to the ERBB1, ERBB2 and ERBB3 receptors.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LY3461767 LY-3461767 Phase 1 Clinical Eli Lilly And Company Heart Failure Details
LY3461767 LY-3461767 Phase 1 Clinical Eli Lilly And Company Heart Failure Details

This web search service is supported by Google Inc.

totop

Nachricht schicken